Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Boule Diagnostics ABBDABF 47 PS Ratio is 5.98 as of Jul. 14, 2026, which is 195% above its 10-year median of 2.03. GuruFocus rates BDABF with a GF Score™ of 47/100 and a GF Value™ of $14.73. The stock has 2 warning signs investors should review. Among 806 Medical Devices & Instruments companies, Boule Diagnostics AB ranks better than 96.15% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Boule Diagnostics AB's share price is $7.84.
Boule Diagnostics AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $1.31. Hence, Boule Diagnostics AB's PS Ratio for today is 5.98.
The historical rank and industry rank for Boule Diagnostics AB's PS Ratio or its related term are showing as below:
BDABF'
s PS Ratio Range Over the Past 10 Years
Min: 0.26 Med: 2.03 Max: 4.71
Current: 0.31
During the past 13 years, Boule Diagnostics AB's highest PS Ratio was 4.71. The lowest was 0.26. And the median was 2.03.
BDABF's PS Ratio is ranked better than 96.15% of 806
companies
in the Medical Devices & Instruments industry
Industry Median: 2.88
vs BDABF: 0.31
Boule Diagnostics AB revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Boule Diagnostics AB was -8.50% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -13.10% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -3.80% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 0.20% per year.
During the past 13 years, Boule Diagnostics AB's highest 3-Year average Revenue per Share Growth Rate was 11.80% per year. The lowest was -13.10% per year. And the median was 3.20% per year.
Back to Basics: PS Ratio
Boule Diagnostics AB (OTCPK:BDABF) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Boule Diagnostics AB PS Ratio Related Terms
Boule Diagnostics AB PS Ratio Historical Data
* Premium members only.
The historical data trend for Boule Diagnostics AB's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Boule Diagnostics AB's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Boule Diagnostics AB PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Boule Diagnostics AB's PS Ratio distribution charts can be found below:
* The bar in red indicates where Boule Diagnostics AB's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Boule Diagnostics AB's Share Price of today is $7.84. Boule Diagnostics AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.31.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Boule Diagnostics AB (BDABF) has a PS Ratio of 5.98 as of Jul. 14, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Boule Diagnostics AB and its competitors. This is 195% above median its historical median of 2.03. Over the past decade, Boule Diagnostics AB's PS Ratio has ranged from 0.26 to 4.71. According to the industry distribution chart, Boule Diagnostics AB ranks #31 out of 806 companies in the Medical Devices & Instruments industry, placing it in the top 3.8%.
Is Boule Diagnostics AB's PS Ratio too high?
Boule Diagnostics AB's current PS Ratio of 5.98 is 195% above median its 10-year median of 2.03. Over the past 10 years, this metric has ranged from a low of 0.26 to a high of 4.71. The Medical Devices & Instruments industry median PS Ratio is 2.88. Boule Diagnostics AB's value of 5.98 is 107.6% above this industry median. Based on the distribution chart, Boule Diagnostics AB ranks #31 out of 806 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Boule Diagnostics AB has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does Boule Diagnostics AB's PS Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Boule Diagnostics AB ranks #31 out of 806 companies for PS Ratio. This places Boule Diagnostics AB in the top 4% of its industry — outperforming the majority of peers. The industry median PS Ratio is 2.88. Boule Diagnostics AB's value of 5.98 is 107.6% above this benchmark. Historically, Boule Diagnostics AB's own PS Ratio has ranged from 0.26 to 4.71 over the past decade. While the company's 10-year median is 2.03 vs. the industry median of 2.88, Boule Diagnostics AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Devices & Instruments company?
The median PS Ratio among Medical Devices & Instruments companies is 2.88, based on 806 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Boule Diagnostics AB's current PS Ratio of 5.98 is 107.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Boule Diagnostics AB and its competitors. For the Medical Devices & Instruments industry, the median PS Ratio is 2.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Boule Diagnostics AB's current PS Ratio is 5.98, which is 195% above median its own 10-year median of 2.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Boule Diagnostics AB stock overvalued right now?
Boule Diagnostics AB (BDABF) has a current PS Ratio of 5.98. The stock's GF Value™ is $14.73, compared to a current price of $7.84 — trading 46.8% below its estimated fair value. The current PS Ratio is 5.98, which is 195% above median its 10-year median of 2.03 and 107.6% above the Medical Devices & Instruments industry median of 2.88. Boule Diagnostics AB's overall GF Score™ is 47/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Boule Diagnostics AB (BDABF), the current PS Ratio is 5.98 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Boule Diagnostics AB (BDABF) Overvalued in 2026?
Based on GuruFocus' analysis, Boule Diagnostics AB stock appears to be undervalued.
The current stock price of $7.84 is trading 46.8% below its estimated GF Value™ of $14.73.
Key valuation signals for BDABF:
PS Ratio: 5.98 (195% above median its 10-year median of 2.03)
GF Value™: $14.73 vs. price of $7.84 (46.8% below fair value)
Industry Position: 107.6% above the Medical Devices & Instruments median (#31 of 806)
No single metric tells the full story. See the BDABF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Boule Diagnostics AB is a company operating in the diagnostics market. It is engaged in the development, manufacturing and marketing instruments and consumables for blood diagnostics. The systems are intended for small and medium-sized hospitals, clinics and laboratories within outpatient care. the company operating through two complementary business segments: Diagnostics and OEM CDS. Through its subsidiaries, the company operates in USA ,Asia, Eastern Europe, Latin America Western Europe and Africa / Middle East. The majority revenue is generated from Asia.
47GF Score
Get the complete analysis for BDABF
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BDABF has been successfully added to your 
